Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to
VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of
anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial
carcinoma.